- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01765621
Clinical and Economic Impact of an Electronic Medical Record Interfaced Decision Support System Reinforced With Patient Specific Pharmacogenetic Data for Minimizing Severe Drug-Drug Interactions (DDI+)
October 20, 2014 updated by: Leumit Health Services
Clinical and Economic Impact of a Web Based, Electronic Medical Record Interfaced Electronic Decision Support System Incorporating Pharmacogenetic Evaluation for Physicians Intended, Mainly for Drug-drug Interaction. A Controlled Study in an Ambulatory Health Maintenance Organization Population
Leumit Health Services, an health maintenance organization operating in Israel, will incorporate a web-based, decision support system for handling drug-drug interactions and drug information, termed DDI+ reinforced with patient specific pharmacogenetic data.
The investigators hypothesize that implementing such a system will reduce health-care expenditures (e.g., hospital admissions, referrals to ERs, Imaging procedures).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
973
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tel-Aviv, Israel
- Leumit Health Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Number of chronic concomitant drugs ≥5
- treated with 1 or more drugs with a well established interaction with 1 or more of the following CYP450 enzymes: 2c9, 2c19, 2d6
Exclusion Criteria:
- Patients diagnosed with HIV/AIDS, and/or viral hepatitis B or C
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DDI+ and Pharmacogenetic data
DDI+ System and Pharmacogenetic data
|
|
No Intervention: Standard Care
Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hospital Admissions
Time Frame: up to 12 month post initiation
|
up to 12 month post initiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
January 9, 2013
First Submitted That Met QC Criteria
January 9, 2013
First Posted (Estimate)
January 10, 2013
Study Record Updates
Last Update Posted (Estimate)
October 21, 2014
Last Update Submitted That Met QC Criteria
October 20, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- LHS022013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthcare
-
Leumit Health ServicesCompleted
-
Seattle Children's HospitalChildren's Hospital of PhiladelphiaNot yet recruitingPatient-provider Communication | Healthcare Inequities | General Pediatric Medical Conditions | Healthcare System Navigation
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Assistance Publique - Hôpitaux de ParisUnknown
-
VA Office of Research and DevelopmentCompletedMental Health | Healthcare DisparitiesUnited States
-
National Taiwan University HospitalUnknown
-
Center for Primary Care and Public Health (Unisante)...University of Lausanne Hospitals; Institut et Haute Ecole de la Santé la SourceRecruitingInformal Caregiver | Healthcare ProfessionalSwitzerland
-
University of CincinnatiOhio Third Frontier; Wright Center of Innovation in Biomedical ImagingActive, not recruitingHealthcare Facility Environment - ImagingUnited States
-
Memorial Sloan Kettering Cancer CenterSOUTH ASIAN COUNCIL FOR SOCIAL SERVICESActive, not recruitingHealthcare Access for Taxi DriversUnited States
-
Denver Health and Hospital AuthorityUniversity of Colorado, DenverCompletedBacterial Contamination of Healthcare Worker UniformsUnited States
Clinical Trials on DDI+ System and Pharmacogenetic Data
-
Avera McKennan Hospital & University Health CenterCompletedMajor Depressive DisorderUnited States
-
Medstar Health Research InstituteKailos Genetics, Inc.Active, not recruitingChronic PainUnited States
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Istituto Ortopedico RizzoliRegione Emilia Romagna - Italy within PRU-Liberati projectCompletedRheumatoid ArthritisItaly
-
Anna VlasovaRussian Medical Academy of Continuous Professional Education; Morozov Children...CompletedDrug TherapyRussian Federation
-
QualissimaCompletedSchizophrenia, Undifferentiated TypeFrance
-
Genelex CorporationHarding UniversityCompletedDrug Interaction Potentiation | Adverse Drug Events | Adverse Drug Reactions | Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant | Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant | Drug Metabolism, Poor, CYP2D6-RELATED | Drug Metabolism, Poor, CYP2C19-RELATED | Cytochrome P450 Enzyme... and other conditionsUnited States
-
Duke UniversityActive, not recruitingDepression | Chronic Pain | Acute PainUnited States
-
Duke UniversityNational Human Genome Research Institute (NHGRI)Active, not recruitingChronic PainUnited States
-
Duke UniversityNational Human Genome Research Institute (NHGRI)Active, not recruitingAcute PainUnited States